Canada Antipsychotic Drugs Market

Canada Antipsychotic Drugs Market Size Insights Forecasts to 2035

• The Canada Antipsychotic Drugs Market Size was estimated at USD 500.36 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.78% from 2025 to 2035
• The Canada Antipsychotic Drugs Market Size is Expected to Reach USD 836.55 Million by 2035

The Canada Antipsychotic Drugs Market Size is anticipated to Reach USD 836.55 Million by 2035, Growing at a CAGR of 4.78% from 2025 to 2035. The increase in mental illnesses worldwide is currently putting strain on healthcare systems and service providers. The government is concentrating on developing high-quality of trustworthy information regarding illnesses and the systems that are connected to them. Additionally, market players are investing substantial resources and providing their resources to develop safe, effective medications that can be used to treat mental illnesses.

Market Overview

The market for antipsychotic drugs in Canada is a segment of the pharmaceutical industry devoted to drugs used to treat mental health conditions like depression, bipolar disorder, and schizophrenia. One of the disease groups that is expected to see a substantial increase in patients worldwide in the current healthcare environment is the category of mental diseases. Dopamine is a crucial neurotransmitter that is primarily impacted by antipsychotics. Psychosis is an important indicator of mental illness because it causes the patient to lose their sense of reality, which makes it difficult for them to process information. Antipsychotics are drugs that treat a variety of emotional and mental disorders, including psychosis and other severe mental illnesses. These drugs assist in treating the symptoms of psychosis as well as other mental illnesses that may contribute to it, such as mood disorders and bipolar disorder. They function by altering the brain's levels of neurotransmitters, which are chemicals that carry messages from one part of the brain to another. Sunshine Biopharma enters the Canadian market for the $1.2 billion global market for generic lurasidone for schizophrenia. Canada has the eighth-largest pharmaceutical market in the world, despite accounting for only 2.2% of the global market. By 2032, the $9.4 billion generic drug market in Canada is projected to grow to $19.2 billion.

Report Coverage

This research report categorises the market for the Canada antipsychotic drugs market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada antipsychotic drugs market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada antipsychotic drugs market.

Driving Factors

Several important factors are driving the market for antipsychotic medications in Canada, such as the demand for antipsychotic drugs is greatly driven by the increasing prevalence of mental health conditions like dementia, bipolar disorder, and schizophrenia. The market grows as more patients seek treatment as a result of increased awareness and de-stigmatisation of mental illnesses. Pharmacological developments have produced more effective and less harmful newer-generation antipsychotics, increasing their uptake rates. Market growth is also supported by increased government funding and programs targeted at enhancing access to mental healthcare in Canada, such as large investments in mental health and addiction services totalling CAD 4.5 billion over five years. Combining antipsychotic medications with telemedicine and digital health technologies improves patient management and treatment compliance while creating new growth opportunities.

Restraining Factors

The market for antipsychotic medications in Canada is hampered by some issues. Accessibility and the launch of new medications are further limited by high treatment costs and regulatory obstacles. Furthermore, underdiagnosis and undermanagement of conditions can result from the stigma associated with mental illness. Pricing and profitability are also impacted by generic drug competition in the market.

Market Segmentation

The Canada antipsychotic drugs market share is classified into therapeutic classes and diseases.  

• The second-generation segment dominated in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The Canada antipsychotic drugs market is segmented by therapeutic classs into first generation, second generation, and third generation. Among these, the second-generation segment dominated in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The dominance of this market segment is caused by the overwhelming presence of second-generation pharmaceuticals on the international market. Additionally, this market's growth will be aided by the medications' increased safety and efficacy from this generation.

• The schizophrenia segment held a substantial share in 2024 and is projected to grow at a rapid pace over the forecast period.

The Canada antipsychotic drugs market is divided by diseases into schizophrenia, bipolar disorder, unipolar depression, dementia, and other diseases. Among these, the schizophrenia segment held a substantial share in 2024 and is projected to grow at a significant CAGR during the forecast period. The category of schizophrenia is increasing due to the high prevalence of the disease globally and the numerous product launches in this market. The bipolar disorder market is expected to hold the second-largest market share due to the widespread use of these medications to stabilise the symptoms of the disease.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Canada antipsychotic drugs market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Janssen (J&J)
• Pfizer
• Eli Lilly
• Otsuka Canada
• AstraZeneca
• Teva Canada
• Apotex
• Others

Recent Developments:

• In September 2025, Orimed Pharma launched Pr Solufy in Canada, a new liquid formulation of aripiprazole designed to improve treatment accessibility for patients with psychiatric conditions. Orimed Pharma is meeting a clinical need by providing a customised solution for patients who need a solid form substitute.
• In May 2025, Viatris launched Gen-Clozapine, the first orally disintegrating tablet (ODT) formulation of clozapine in Canada, offering a new treatment option for patients with treatment-resistant schizophrenia. The oral disintegrating tablet of clozapine, the only antipsychotic approved for treatment-resistant schizophrenia, is now available for the first time in Canada.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Canada, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the Canada Antipsychotic Drugs Market based on the below-mentioned segments:

Canada Antipsychotic Drugs Market, By Therapeutic Classs

• First Generation
• Second Generation
• Third Generation

Canada Antipsychotic Drugs Market, By Diseases  

• Schizophrenia
• Bipolar Disorder
• Unipolar Depression
• Dementia
• Other Diseases